Two highly similar LAEDDTNAQKT and LTDKIGTEI epitopes in G glycoprotein may be useful for effective epitope based vaccine design against pathogenic Henipavirus

Parvege, Md. Masud; Rahman, M. Shaminur; Nibir, Yead Morshed; Hossain, Mohammad Shahnoor

doi:10.1016/j.compbiolchem.2016.03.001

Cited by 13 publications

(7 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…as viral vectors for the vaccine development (Satterfield, Dawes, et al, 2016). Some groups have also put forward in silico approaches to design epitope-based vaccine candidates against the Glycoprotein, Fusion protein or the RdRp of Nipah virus (Kamthania & Sharma, 2015;Parvege, Rahman, Nibir, & Hossain, 2016;Ravichandran, Venkatesan, & Febin Prabhu Dass, 2019;C. K. Saha, Mahbub Hasan, Saddam Hossain, Asraful Jahan, & Azad, 2017;Sakib, Islam, Hasan, & Nabi, 2014).…”

Section: Introductionmentioning

confidence: 99%

Designing of a multi-epitope vaccine candidate against Nipah virus by in silico approach: a putative prophylactic solution for the deadly virus

Majee

Jain

Kumar

2020

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

Nipah virus (NPV) is one of the most notorious viruses with a very high fatality rate. Because of the recurrent advent of this virus and its severe neurological implications, often leading to high mortality, the WHO R&D Blueprint, 2018 has listed the Nipah virus as one of the emerging infectious diseases requiring urgent research and development effort. Yet there is a major layback in the development of effective vaccines or drugs against NPV. In this study, we have designed a stable multivalent vaccine combining several T-cell and B-cell epitopes of the essential Nipah viral proteins with the help of different ligands and adjuvants which can effectively induce both humoral and cellular immune responses in human. Different advanced immune-informatic tools confirm the stability, high immunogenicity and least allergenicity of the vaccine candidate. The standard molecular dynamic cascade analysis validates the stable interaction of the vaccine construct with the human Toll-like receptor 3 (TLR3) complex. Later, codon optimization and in silico cloning in a known pET28a vector system shows the possibility for the expression of this vaccine in a simple organism like E.coli. It is believed that with further in vitro and in vivo validation, this vaccine construct can pose to be a better prophylactic solution to the Nipah viral disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Designing of a multi-epitope vaccine candidate against Nipah virus by in silico approach: a putative prophylactic solution for the deadly virus

Majee

Jain

Kumar

2020

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

show abstract

“…To visualize these host-virus interactions, we plotted the 101 PPIs as a network schematic (Fig. 2), with inclusion of the PPIs for cellular proteins derived from the IntACT (https://www.ebi.ac.uk/intact/) (35) and String (http://string-db.org/) (36) data- [37][38][39][40][41][42] and support the quality of our approach. Surprisingly, we also detected an interaction between the W protein and STAT4, although a previously reported interaction with STAT1 went undetected (18).…”

Section: Resultsmentioning

confidence: 89%

Exploring the Human-Nipah Virus Protein-Protein Interactome

Martínez-Gil

Vera-Velasco

Mingarro

2017

J Virol

View full text Add to dashboard Cite

Nipah virus is an emerging, highly pathogenic, zoonotic virus of the family. Human transmission occurs by close contact with infected animals, the consumption of contaminated food, or, occasionally, via other infected individuals. Currently, we lack therapeutic or prophylactic treatments for Nipah virus. To develop these agents we must now improve our understanding of the host-virus interactions that underpin a productive infection. This aim led us to perform the present work, in which we identified 101 human-Nipah virus protein-protein interactions (PPIs), most of which (88) are novel. This data set provides a comprehensive view of the host complexes that are manipulated by viral proteins. Host targets include the PRP19 complex and the microRNA (miRNA) processing machinery. Furthermore, we explored the biologic consequences of the interaction with the PRP19 complex and found that the Nipah virus W protein is capable of altering p53 control and gene expression. We anticipate that these data will help in guiding the development of novel interventional strategies to counter this emerging viral threat. Nipah virus is a recently discovered virus that infects a wide range of mammals, including humans. Since its discovery there have been yearly outbreaks, and in some of them the mortality rate has reached 100% of the confirmed cases. However, the study of Nipah virus has been largely neglected, and currently we lack treatments for this infection. To develop these agents we must now improve our understanding of the host-virus interactions that underpin a productive infection. In the present work, we identified 101 human-Nipah virus protein-protein interactions using an affinity purification approach coupled with mass spectrometry. Additionally, we explored the cellular consequences of some of these interactions. Globally, this data set offers a comprehensive and detailed view of the host machinery's contribution to the Nipah virus's life cycle. Furthermore, our data present a large number of putative drug targets that could be exploited for the treatment of this infection.

show abstract

“…Several vaccine development strategies have recently been studied in small-animal models, including chimeric rabies-based 88 , virus-like particle (VLP)-based 89 , adenovirus-based 90 , and epitope-based 91, 92 vaccines. Those approaches induced a protection against NiV by triggering a specific response against its envelope glycoprotein G that will require further development using non-human primates to evaluate their efficiency and safety.…”

Section: New Strategies To Control Nipah Virus Infectionmentioning

confidence: 99%

Recent advances in the understanding of Nipah virus immunopathogenesis and anti-viral approaches

2019

View full text Add to dashboard Cite

Nipah virus (NiV) is a highly lethal zoonotic paramyxovirus that emerged at the end of last century as a human pathogen capable of causing severe acute respiratory infection and encephalitis. Although NiV provokes serious diseases in numerous mammalian species, the infection seems to be asymptomatic in NiV natural hosts, the fruit bats, which provide a continuous virus source for further outbreaks. Consecutive human-to-human transmission has been frequently observed during outbreaks in Bangladesh and India. NiV was shown to interfere with the innate immune response and interferon type I signaling, restraining the anti-viral response and permitting viral spread. Studies of adaptive immunity in infected patients and animal models have suggested an unbalanced immune response during NiV infection. Here, we summarize some of the recent studies of NiV pathogenesis and NiV-induced modulation of both innate and adaptive immune responses, as well as the development of novel prophylactic and therapeutic approaches, necessary to control this highly lethal emerging infection.

show abstract

Two highly similar LAEDDTNAQKT and LTDKIGTEI epitopes in G glycoprotein may be useful for effective epitope based vaccine design against pathogenic Henipavirus

Cited by 13 publications

References 78 publications

Designing of a multi-epitope vaccine candidate against Nipah virus by in silico approach: a putative prophylactic solution for the deadly virus

Designing of a multi-epitope vaccine candidate against Nipah virus by in silico approach: a putative prophylactic solution for the deadly virus

Exploring the Human-Nipah Virus Protein-Protein Interactome

Recent advances in the understanding of Nipah virus immunopathogenesis and anti-viral approaches

Contact Info

Product

Resources

About